However, this represents a small population size and it known that baseline levels of PARP activity vary markedly in both cancer patients and healthy human volunteers (Zaremba et al, 2011), and may result in different clinical outcomes from the same degree of PARP inhibition. This evidence concerns the gene PARP1 and cancer.